# Pyoderma Gangrenosum

Pyoderma gangrenosum requires rapid recognition of an inflammatory ulcer pattern while actively excluding infection, vascular disease, vasculitis, and malignancy. Biopsy and cultures should precede immunosuppression when feasible; avoid traumatic debridement once pathergy is suspected.

**Clinical question:** How should physicians confirm pyoderma gangrenosum, exclude dangerous mimics, and treat active disease without provoking pathergy?

Updated: 2026-09-15T23:44:44.853839+00:00

## What matters in practice
- Treat pyoderma gangrenosum as a clinicopathologic diagnosis requiring exclusion of infection and other ulcer causes; approximately 10% of institutional PG diagnoses in one series were ultimately mimics, including vascular disease, thrombophilic ulcers, vasculitis, lymphoma, and deep fungal infection. [2]
- For ulcerative PG, obtain an ulcer-edge biopsy; the Delphi framework uses neutrophilic infiltrate as its major criterion plus at least 4 of 8 minor criteria, including exclusion of infection and compatible morphology or history. [11][18]
- Rapid postoperative ulcer enlargement beyond the incision, particularly after debridement or other trauma, should prompt consideration of postsurgical PG and reassessment before further operative debridement. [14][15][20]
- Use local high-potency corticosteroid or calcineurin-inhibitor therapy for limited superficial disease; escalate to systemic corticosteroids or cyclosporine for severe disease, and consider systemic therapy for numerous ulcers or total ulcer area greater than 4 cm². [20][23]
- Infliximab 5 mg/kg is the biologic with randomized controlled-trial evidence in classic PG; reported clinical benefit was 69% by week 6, but TNF-alpha inhibitors require attention to serious infection and other safety risks. [22][23]

## When to suspect PG and when not to delay infection evaluation

The central error is labeling a destructive ulcer PG before testing plausible infectious, vascular, malignant, and inflammatory alternatives.

Suspect ulcerative PG when a papule, pustule, vesicle, or nodule evolves rapidly into a markedly painful ulcer with peripheral erythema, a violaceous undermined border, and progressive tissue loss. Anterior lower-leg involvement, multiple ulcers, cribriform healed scars, pathergy, inflammatory bowel disease (IBD), and inflammatory arthritis each increase diagnostic support. [11][16][18]

Do not use morphology alone to justify immunosuppression. Vascular ulcers, antiphospholipid-associated ulcers, vasculitis, lymphoma, and deep fungal infection have been misdiagnosed as PG; one institutional reassessment found an alternative diagnosis in roughly 10% of patients initially labeled PG. [2] The practical implication is to obtain tissue from an active ulcer edge and assess for infection before committing to systemic immunosuppression whenever the patient is clinically stable. [11][18]

A rapidly advancing painful postoperative wound is a high-stakes branch point. Postsurgical PG can begin after an initially normal wound interval of 4 days to 6 weeks, then develop coalescing dehiscence and ulceration that extends beyond the operative field. It is commonly mistaken for pyogenic or necrotizing infection, and repeated debridement can accelerate necrosis through pathergy. [14][15][20]
- Prioritize an infectious or necrotizing process when the presentation requires urgent source-control assessment; collect lesion-edge tissue for histopathology and infection exclusion rather than assuming sterile inflammation. [11][18][20]
- Reconsider PG when an apparent postoperative infection deteriorates despite antimicrobial therapy and serial debridement, especially when ulceration expands beyond the incision with violaceous undermining. [14][15][20]
- Avoid elective sharp debridement, grafting, or closure during uncontrolled suspected PG unless another diagnosis requires surgery or reconstruction is necessary after inflammatory control; local trauma may trigger new or enlarged lesions. [7][14][15]

*Features that shift the immediate diagnostic pathway for a rapidly progressive ulcer. [2][11][14][15][20]*

| Clinical branch | Findings that support the branch | Immediate action |
| --- | --- | --- |
| Ulcerative PG | Rapid painful ulcer; erythematous, violaceous, undermined border; pathergy; compatible IBD or inflammatory arthritis history; cribriform scars. [11][18] | Obtain ulcer-edge biopsy and exclude infection; limit traumatic wound manipulation while diagnostic assessment proceeds. [11][18] |
| Postsurgical PG | Dehiscence or ulceration after surgery, often extending beyond the wound; worsening after debridement or other trauma. [14][15][20] | Pause further nonessential debridement; obtain dermatology and surgical reassessment, tissue evaluation, and infection exclusion. [14][15][20] |
| PG mimic | Vascular disease, thrombophilic ulceration, vasculitis, lymphoma, or deep fungal infection can mimic PG. [2] | Direct further evaluation to the leading alternative diagnosis before escalating immunosuppression. [2] |

## Use ulcer-edge biopsy and Delphi criteria as a structured diagnostic framework

No single study establishes PG; biopsy is most useful when interpreted with morphology, cultures, and exclusion of competing etiologies.

Biopsy the active ulcer edge rather than only the necrotic center. In the 2018 Delphi framework for ulcerative PG, the major criterion is an ulcer-edge biopsy showing neutrophilic infiltrate. The framework is met by the major criterion plus at least 4 of 8 minor criteria. [11][18] Histology also serves the essential exclusion function: it can help identify infection or other etiologies in an ulcer that clinically resembles PG. [15]

Score minor criteria deliberately: exclusion of infection; pathergy; personal history of IBD or inflammatory arthritis; a papule, pustule, or vesicle ulcerating within 4 days; peripheral erythema, an undermined border, and tenderness; multiple ulcers with at least one on an anterior lower leg; cribriform or wrinkled-paper scars; and reduction in ulcer size within 1 month after immunosuppressive treatment. [11][18] In a validation described for this framework, the criteria had 86% sensitivity and 90% specificity against known cases and mimics. [16]

Interpret a nondiagnostic biopsy cautiously. Chronic ulcer histology may be nonspecific, and a multicenter retrospective report cited neutrophils in only 7% to 11% of PG biopsies; therefore, absent neutrophilic infiltrate should reopen the differential rather than automatically exclude a clinically compelling case. [17] Conversely, a neutrophilic infiltrate does not replace microbiologic and clinicopathologic exclusion of infection and other mimics. [11][17]
- Document ulcer number, location, border character, tenderness, scar pattern, antecedent lesion type, trauma exposure, and timing of progression before treatment; these observations map directly to Delphi minor criteria. [11][18]
- Ask specifically about IBD and inflammatory arthritis, because either history is a Delphi minor criterion and may influence selection of systemic therapy that treats both disorders. [11][18][22]
- Use early reduction in ulcer size after immunosuppression as supportive evidence at the 1-month reassessment, not as a substitute for initial infection exclusion. [11][18]

*Delphi diagnostic criteria for ulcerative pyoderma gangrenosum. [11][18]*

| Criterion type | Criterion | How it changes confidence |
| --- | --- | --- |
| Major | Ulcer-edge biopsy demonstrates neutrophilic infiltrate. [11][18] | Required major component in the Delphi framework. [11][18] |
| Minor | Exclusion of infection; pathergy; IBD or inflammatory arthritis; papule, pustule, or vesicle ulcerating within 4 days. [11][18] | Each supports PG after an appropriate competing-diagnosis assessment. [11][18] |
| Minor | Peripheral erythema, undermined border, and tenderness; multiple ulcers including at least one anterior lower-leg ulcer; cribriform scars; ulcer reduction within 1 month of immunosuppression. [11][18] | Use with the major criterion; at least 4 of 8 minor criteria are indicated in the framework. [18] |

## Control inflammation while minimizing pathergy and preserving the wound bed

Match treatment intensity to ulcer burden and rate of progression, while avoiding interventions likely to enlarge an active lesion.

For a single superficial or mild lesion, use local anti-inflammatory therapy: high-potency topical corticosteroid or a topical calcineurin inhibitor is described as first-line treatment. In a prospective cohort summarized in the literature, 44% of lesions healed by 6 months and 15% of those patients subsequently had recurrent lesions. [20] This approach is best reserved for limited disease without rapid extension, extensive ulceration, or a need for rapid systemic control.

Escalate to systemic therapy for numerous ulcers or total ulcer area greater than 4 cm². Systemic corticosteroids and cyclosporine are established rapid-onset options for severe PG. [20][23] The reviewed evidence identifies prednisolone and cyclosporine as systemic agents with level 1B evidence, but specific regimen selection and dosing must be individualized because the cited material does not provide a standardized dose protocol. [23]

Pair anti-inflammatory treatment with nontraumatic local wound care and active pain management. Because pathergy can follow debridement, bandaging, surgery, and other local trauma, avoid aggressive mechanical manipulation during active progression. [7][15] If reconstruction becomes necessary for a large defect, coordinate it after inflammatory control; no standard reconstructive approach exists for postsurgical PG. [12]
- Limited, superficial disease: high-potency topical corticosteroid or topical calcineurin inhibitor; reassess objective ulcer dimensions and edge activity over the first month. [20][11]
- Extensive, multiple, or rapidly progressive disease: initiate systemic corticosteroid or cyclosporine-based therapy after infection evaluation and diagnostic reassessment. [20][23]
- Worsening after a procedure or debridement: treat pathergy as a possible driver, stop further nonessential trauma, and reassess the diagnosis rather than reflexively escalating surgery. [14][15][20]

### Postsurgical PG

Postsurgical PG is often recognized late: a practical review of 28 reported surgical cases found mean times of 5.5 days to presentation and 17 days to diagnosis. [12] In a postoperative wound that is expanding despite antibiotics or debridement, obtain an ulcer-edge biopsy and infection assessment, involve dermatology early, and avoid additional nonessential operative trauma while systemic inflammatory treatment is considered. [14][15][20]

When a future operation is unavoidable in a patient with known postsurgical PG, the literature identifies prophylactic immunosuppression before subsequent surgery as a main management principle, but does not establish a uniform regimen. [14] Make that decision jointly with the treating dermatologist and surgical team rather than applying a fixed perioperative protocol.

*Treatment intensity by clinical burden and procedural risk. [20][23]*

| Clinical situation | Preferred treatment direction | Reassessment trigger |
| --- | --- | --- |
| Single or superficial mild lesion | High-potency topical corticosteroid or topical calcineurin inhibitor. [20] | Failure to reduce ulcer burden or continued progression warrants systemic-treatment assessment. [11][20] |
| Numerous ulcers or total ulcer area >4 cm² | Systemic corticosteroids and/or cyclosporine; these agents have rapid onset and are standard systemic options. [20][23] | Assess ulcer dimensions and edge inflammation; reduction within 1 month supports the PG diagnosis. [11][18] |
| Postsurgical expansion or pathergy | Avoid further nonessential debridement or closure; coordinate medical control and reconstruction planning. [14][15][20] | Persistent concern for infection or another mimic requires repeat diagnostic reassessment. [2][11][20] |

## When to consider biologic therapy

Biologic selection should account for PG severity, prior response, comorbid IBD, and TNF-inhibitor safety considerations.

Consider a biologic when PG is inadequately controlled with conventional systemic therapy, when steroid-sparing treatment is needed, or when a coexisting inflammatory disorder makes a shared therapeutic target advantageous. Infliximab is the biologic with the strongest controlled evidence: 5 mg/kg was superior to placebo in a randomized trial, with clinical benefit reported in 69% of patients by week 6. [22][23] Another summary of the trial reported response at 2 weeks in 46% of infliximab-treated patients versus 21% with placebo. [24]

For PG associated with IBD, anti-TNF treatment may benefit both skin and bowel disease. Infliximab and adalimumab have been reported as effective, whereas etanercept is not effective for IBD and should not be selected when control of IBD is also a treatment objective. [22] This distinction matters even if etanercept has case-based PG activity.

Balance potential benefit against safety. TNF-alpha inhibitors carry increased risk of serious infections that may lead to hospitalization or death; reported concerns with infliximab and adalimumab also include heart failure, infection, and malignancy. [21][23] Before initiating a TNF inhibitor, ensure that the ulcer has been evaluated for infection and review contraindication-relevant comorbidity and concurrent immunosuppression.
- Infliximab: 5 mg/kg; only TNF-alpha inhibitor identified in the cited literature as validated by a randomized, double-blind, placebo-controlled trial for classic PG. [21][22]
- Adalimumab and other biologics have supportive nonrandomized or case-based evidence; do not equate reported case-series response rates with randomized comparative efficacy. [21][23]
- Anakinra has reported activity in PAPA syndrome, making the associated autoinflammatory syndrome clinically relevant to agent selection. [22]

*Biologic treatment decisions supported by the available PG literature. [21][22][23][24]*

| Agent or class | Evidence and role | Key selection or safety issue |
| --- | --- | --- |
| Infliximab | 5 mg/kg; randomized controlled evidence and reported clinical benefit in 69% by week 6. [22][23] | Evaluate for infection and weigh serious infection, heart failure, and malignancy risks associated with TNF-alpha inhibition. [21][23] |
| Adalimumab | Reported successful use; evidence base is less robust than for infliximab. [21][23] | May be relevant when concomitant IBD treatment is desired; apply TNF-inhibitor safety assessment. [21][22] |
| Etanercept | Reported PG responses in case literature. [22] | Not effective for IBD; avoid choosing it when bowel-disease control is a concurrent objective. [22] |
| Anakinra | Reported very good response in PAPA syndrome. [22] | Consider when the clinical context suggests PAPA syndrome rather than idiopathic ulcerative PG. [22] |

## Measure response, reassess nonresponse, and address associated disease

The response assessment should distinguish improving inflammatory activity from an enlarging wound caused by ongoing PG, trauma, infection, or a mistaken diagnosis.

At treatment initiation, record ulcer dimensions, number, location, border undermining, peripheral erythema, tenderness, drainage, and any new trauma-associated lesions. Reassess objectively within 1 month: reduction in ulcer size after immunosuppressive medication is a Delphi minor diagnostic criterion, whereas persistent expansion should prompt reassessment for infection, vascular or thrombotic disease, vasculitis, neoplasm, and continued pathergy. [11][18][2]

Evaluate associated systemic disease because PG may coexist with IBD, inflammatory arthritis, hematologic malignancy, autoimmune disease, or inherited inflammatory syndromes. [5][19][20] Treating the associated disorder may hasten PG resolution, and selection of a systemic agent can be coordinated with the therapy required for the underlying condition. [20][22]

Expect healing to be slow even after inflammatory control. One surgical review cited average complete healing at 20.37 weeks. [16] Do not interpret delayed epithelial closure alone as failed immunosuppression if border activity and ulcer dimensions are improving; however, new ulceration after local trauma requires renewed attention to pathergy. [7][15]
- At every reassessment, compare measured ulcer area and active-edge inflammation with baseline rather than relying on subjective impressions. A decrease in ulcer size within 1 month is diagnostically supportive. [11][18]
- If ulcers enlarge despite immunosuppression, repeat the mimic assessment rather than simply increasing immunosuppression; vascular disease, thrombophilia, vasculitis, lymphoma, and deep fungal infection are established misdiagnosis categories. [2]
- Coordinate dermatology, wound care, surgery, and the specialty managing IBD, arthritis, hematologic disease, or an autoinflammatory syndrome when these conditions are present. [3][5][19][20]

*Response-based follow-up for suspected or confirmed PG. [2][11][16][18]*

| Follow-up finding | Interpretation | Next action |
| --- | --- | --- |
| Ulcer size decreases within 1 month of immunosuppression | Supports PG within the Delphi minor criteria. [11][18] | Continue the selected treatment strategy while monitoring wound progression and treatment safety. |
| Persistent enlargement, new lesions, or worsening after local trauma | May reflect uncontrolled PG with pathergy, but infection or a mimic remains possible. [2][7][15] | Reassess tissue diagnosis and infection exclusion; avoid further nonessential traumatic procedures. [2][11][15] |
| Inflammatory edge improves but closure is slow | Healing can require weeks; average complete healing of 20.37 weeks was reported in one review. [16] | Continue measured wound follow-up and reserve reconstruction planning for controlled inflammatory disease. [12][16] |

## Common questions

### Should a suspected PG ulcer be surgically debrided?

Avoid nonessential aggressive debridement during active suspected PG because trauma can provoke pathergy and accelerate tissue loss. Reassess for infection or another surgical indication, and plan reconstruction only with inflammatory disease control and multidisciplinary input. [7][14][15][20]

### Does a negative neutrophilic biopsy exclude pyoderma gangrenosum?

No. The Delphi framework uses ulcer-edge neutrophilic infiltrate as its major criterion, but chronic ulcer histology may be nonspecific and neutrophils were reported in only 7% to 11% of biopsies in one retrospective analysis. A negative result should intensify clinicopathologic review and mimic exclusion. [11][17][18]

## References
1. [PDF] 04-28-22 FDA Wound Healing Workshop (Full Transcript) — www.fda.gov — https://www.fda.gov/media/167141/download
2. Pyoderma Gangrenosum Is a Diagnosis of Exclusion | NEJM Clinician — clinician.nejm.org — https://clinician.nejm.org/pyoderma-gangrenosum-diagnosis-exclusion-JD200211270000002
3. Diagnosis and management of parastomal pyoderma gangrenosum — academic.oup.com — https://academic.oup.com/gastro/article/doi/10.1093/gastro/got013/575696
4. Postoperative Pyoderma Gangrenosum: A Clinical Review of Published Cases - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0025619616301835
5. Reconstructive microsurgical approach for the treatment of pyoderma gangrenosum — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S174868151730339X
6. Pyoderma gangrenosum: A report of a rare complication after knee arthroplasty requiring muscle flap cover supplemented by negative pressure therapy and hyperbaric oxygen - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1748681511001355
7. Third European Evidence-based Consensus on Diagnosis and ... — academic.oup.com — https://academic.oup.com/ecco-jcc/article/11/6/649/2966917
8. A decade-long case of pyoderma gangrenosum successfully treated ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2667396725000898
9. a case report and review of the literature | Skin Health and Disease — academic.oup.com — https://academic.oup.com/skinhd/advance-article/doi/10.1093/skinhd/vzag103/8728481
10. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory ... — academic.oup.com — https://academic.oup.com/ecco-jcc/article/18/1/1/7205776
11. Clinical guidance of pyoderma gangrenosum 2022 — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/1346-8138.16845
12. Postsurgical Pyoderma Gangrenosum Requiring... : Plastic and Reconstructive Surgery - Global Open — journals.lww.com — https://journals.lww.com/prsgo/fulltext/2024/01000/postsurgical_pyoderma_gangrenosum_requiring.22.aspx
13. Clinical characteristics of pyoderma gangrenosum: Case... : Medicine — journals.lww.com — https://journals.lww.com/md-journal/fulltext/2024/09130/clinical_characteristics_of_pyoderma_gangrenosum_.94.aspx
14. Pyoderma gangrenosum: a case report highlighting... : International Journal of Surgery Case Reports — journals.lww.com — https://journals.lww.com/ijscr/fulltext/2026/03000/pyoderma_gangrenosum__a_case_report_highlighting.11.aspx?context=latestarticles
15. Successful Treatment of Pyoderma Gangrenosum after... : Plastic and Reconstructive Surgery – Global Open — journals.lww.com — https://journals.lww.com/prsgo/fulltext/2016/11000/successful_treatment_of_pyoderma_gangrenosum_after.17.aspx
16. Pyoderma Gangrenosum: A Diagnostic Challenge for the Surgical Consultant | ACS — www.facs.org — https://www.facs.org/for-medical-professionals/news-publications/journals/case-reviews/issues/v4n1/harrington-pyoderma-gangrenosum
17. [PDF] Therapeutic and Diagnostic Pearls-30' Mark Lebwohl, MD — facultyadmin.aad.org — https://facultyadmin.aad.org/api/handout/get?handoutId=14831
18. Postsurgical Pyoderma Gangrenosum After Minimally Invasive ... — www.jbjs.org — https://www.jbjs.org/reader.php?rsuite_id=7c1fc4e2-187b-44cc-8ca1-12c44e926fc8&type=pdf&name=JBJS.CC.23.00087.pdf
19. Management of Idiopathic Pyoderma Gangrenosum With Azathioprine As the Primary Adjunct in an Asian Man: A Case Report - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/35746991
20. A Case of Pyoderma Gangrenosum Misdiagnosed as Necrotizing Infection: A Potential Diagnostic Catastrophe - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944231
21. Pyoderma Gangrenosum with Biological Agents Therapy: A Systematic Review - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12716805
22. Pyoderma gangrenosum: challenges and solutions - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4454198
23. Pyoderma Gangrenosum: Treatment Options — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10511384
24. Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5083266

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.